Bibliography
- Hopkins MM , IbarretaD, GaisserS et al. Putting pharmacogenetics into practice. Nat. Biotechnol. 24(4) , 403–410 (2006).
- Hedgecoe A . Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics8(3) , 267–270 (2007).
- Evans WE , RellingMV. Moving towards individualized medicine with pharmacogenomics. Nature429(6990) , 464–468 (2004).
- Lesko LJ , ZinehI. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics11(4) , 507–512 (2010).
- Gurwitz D , ZikaE, HopkinsMM et al. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12(3) , 134–141 (2009).
- Ikediobi ON , ShinJ, NussbaumRL et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86(1) , 28–31 (2009).
- Gurwitz D , MotulskyAG. ‘Drug reactions, enzymes, and biochemical genetics‘: 50 years later. Pharmacogenomics8(11) , 1479–1484 (2007).
- Tamaoki M , GushimaH, TsutaniK. Awareness survey of parties involved in pharmacogenomics in Japan. Pharmacogenomics8(3) , 275–286 (2007).
- Rogausch A , PrauseD, SchallenbergA et al. Patients‘ and physicians‘ perspectives on pharmacogenetic testing. Pharmacogenomics 7(1) , 49–59 (2006).
- Nielsen LF , MoldrupC. The diffusion of innovation: factors influencing the uptake of pharmacogenetics. Community Genet.10(4) , 231–241 (2007).
- Shin J , KayserSR, LangaeeTY. Pharmacogenetics: from discovery to patient care. Am. J. Health Syst. Pharm.66(7) , 625–637 (2009).
- Cascorbi I . The promises of personalized medicine. Eur. J. Clin. Pharmacol.66(8) , 749–754 (2010).
- Fargher EA , EddyC, NewmanW et al. Patients‘ and healthcare professionals‘ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11) , 1511–1519 (2007).
- Woelderink A , IbarretaD, HopkinsMM et al. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6(1) , 3–7 (2006).
- Tamaoki M , GushimaH, TsutaniK. Pharmacogenomics in Asia. Pharmacogenomics5(8) , 1023–1027 (2004).
- Esmerian MO , MitriZ, HabbalMZ et al. The influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J. Clin. Pharmacol. doi: 10.1177/0091270010382910 (2010) (Epub ahead of print).
- Pollack A . Patient‘s DNA may be signal to tailor medication. The New York Times (2008).
- Khoury MJ , FeeroWG, ReyesM et al. The genomic applications in practice and prevention network. Genet. Med. 11(7) , 488–494 (2009).
- Teutsch SM , BradleyLA, PalomakiGE et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet. Med. 11(1) , 3–14 (2009).
- Breckenridge A , LindpaintnerK, LiptonP et al. Pharmacogenetics: ethical problems and solutions. Nat. Rev. Genet. 5(9) , 676–680 (2004).
▪ Websites
- World Economic Outlook Database. WEO Groups and Aggregates Information in April 2010 by the International Monetary Fund www.imf.org/external/pubs/ft/weo/2010/01/weodata/groups.htm
- US FDA. Table of pharmacogenomic biomarkers in drug labels www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm83378.htm
- Presentation at WorldPharma 2010 by Andrew Somogyi: Obstacles to the implementation of Pharmacogenetic Testing in Australia www.worldpharma2010.org/pp/W16.4.pdf
- ACCE Model List of 44 Targeted Questions aimed at a Comprehensive Review of Genetic Testing by the Centers for Disease Control and Prevention www.cdc.gov/genomics/gtesting/acce/acce_proj.htm
- A Public statement by the EU (European Commission and EMEA) and FDA on Guiding Principles for Joint FDA EMEA Voluntary Genomic Data Submission Briefing Meetings www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108660.htm
- The IVD directive and regulations governing the sale of in vitro diagnostic products in the UK by The British In vitro Diagnostics Association (BIVDA) www.bivda.co.uk/Portals/0/BIVDA%20-%20regs%20for%20UK%20paper.pdf